hero image
Scott A. Mosley, PharmD - USC School of Pharmacy. Los Angeles, CA, US

Scott A. Mosley, PharmD Scott A. Mosley, PharmD

Assistant Professor of Clinical Pharmacy | USC School of Pharmacy


Scott Mosley is an expert in pharmacogenomics implementation.

Social Media


Scott Mosley, PharmD, has joined the faculty of the Titus Department of Clinical Pharmacy as assistant professor of clinical pharmacy.

His research is focused in pharmacogenomics implementation, which incorporates genetic information with other clinical factors to optimize drug selection.

He received a B.S. in Biochemical/Biophysical Science from the University of Houston in 2006, then worked as an analytical chemist in a core pharmacology lab for MD Anderson Cancer Center in Houston, TX. He received his PharmD degree from the University of Texas in 2013, and then took a position as a pharmacist with MD Anderson Cancer Center.

He completed a postdoctoral research fellowship at the University of Florida College of Pharmacy in the Center for Pharmacogenomics under the mentorship of Larisa Cavallari, PharmD. During that time he carried out a research protocol to assess the value of utilizing CYP2D6 genotype to guide opioid selection for patients with cancer pain.

Areas of Expertise (5)

Clinical Pharmacy


Personalized Medicine



Education (2)

University of Texas: Pharm.D.

University of Houston: B.S.

Selected Articles (5)

Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial

Contemporary Clinical Trials

Scott A. Mosley et al.

2018 Patients with solid tumors with metastasis and a self-reported pain score ≥ 4/10 are eligible for enrollment and randomized to a genotype-guided or conventional pain management strategy. For patients in the genotype-guided arm, CYP2D6 genotype information is integrated into opioid prescribing decisions. Patients are asked to complete questionnaires regarding their pain, symptoms, and quality of life at baseline and 2, 4, 6, and 8 weeks after enrollment. The primary endpoint is differential change in pain severity by treatment strategy (genotype-guided versus conventional pain management). Secondary endpoints include change in pain and symptom interference with daily living.

view more

Institutional profile: University of Florida health personalized medicine program

Future Medicine

Scott A. Mosley et al.

2017 The University of Florida (UF) Health Personalized Medicine Program launched in 2012 with CYP2C19 genotyping for clopidogrel response at UF Health Shands Hospital. We have since expanded CYP2C19 genotyping to UF Health Jacksonville and established the infrastructure at UF Health to support clinical implementation for five additional gene–drug pairs: TPMT–thiopurines, IFNL3 (IL28B)–PEG IFN-α-based regimens, CYP2D6–opioids, CYP2D6/CYP2C19–antidepressants and CYP2C19–proton pump inhibitors. We are contributing to the evidence based on outcomes with genotype-guided therapy through pragmatic studies of our clinical implementations. In addition, we have developed a broad array of educational programs for providers, trainees and students that incorporate personal genotype evaluation to enhance participant learning.

view more

Utilization of an ex vivo human placental perfusion model to predict potential fetal exposure to carboplatin during pregnancy

American Journal of Obstetrics and Gynecology

Scott A. Mosley

2014 The objective of this study was to determine the fetal drug compartment concentrations when various concentrations of carboplatin cross the placental-trophoblastic barrier and the effect on the fetal kidneys.

view more

Evaluation of liposomal curcumin cytochrome p450 metabolism

Anticancer Research

Scott A. Mosley et al.

2010 High-throughput cytochrome P450 (CYP450) metabolism inhibition assays were conducted in vitro evaluating CYP450 3A4, 2C8, 2C9, and 2D6. An ex vivo model of cryopreserved human hepatocytes was used to evaluate the CYP450 metabolism induction potential of curcumin for CYP P450 3A4, 2C8/2C9, and 2D6.

view more

Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model

Anticancer Research

Scott A. Mosley et al.

2009 The MED determination and optimal schedule was evaluated in female athymic nude mice injected subcutaneously with MiaPaCa-2 cells. Dosing was initiated at an average tumor size of 5mm. For the MED, mice were treated with the following dose levels of liposomal curcumin: no treatment, liposome only, 1 mg/kg, 2 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg and 40 mg/kg given by tail vein injection three times weekly for 28 days. For the optimum dosing schedule, three additional schedules were evaluated and compared to the control of three times weekly; daily (five days per week), every four days, and weekly for 28 days. All mice were weighed and tumor measurements taken three times weekly to evaluate toxicity and efficacy.

view more